Key result
Discharge on torsemide was not associated with a significant difference in one-year all-cause mortality compared to furosemide in patients with chronic heart failure.
Why the study?
Does torsemide or a combination of furosemide and torsemide improve one-year mortality in patients with chronic heart failure compared with furosemide alone?
Cohort (n=956)
No
Does torsemide or a combination of furosemide and torsemide improve one-year mortality in patients with chronic heart failure compared with furosemide alone?
In patients with chronic heart failure, discharge on torsemide or a combination of torsemide and furosemide did not significantly improve one-year mortality compared to furosemide alone after adjusting for baseline differences.
Answers are grounded in this paper and cite their sources.
No mortality difference with torsemide discharge; leaves open optimal loop diuretic selection in chronic HF.
The aim of this study was to investigate the effect on mortality of torsemide and a combination of loop diuretics (furosemide + torsemide) in contemporary practice in patients with chronic heart failure (HF).We investigated patients with HF in the Heart Failure Center of Fuwai Hospital from 2009 to 2013 who were discharged on furosemide, torsemide, or a combination of the 2 drugs. Using inverse probability weighting (IPW) to account for nonrandom selection of diuretic strategies, we assessed the association between different diuretic strategies and mortality.Among 956 patients, 19.7% (n = 188) received furosemide, 36.6% (n = 350) torsemide, and 43.7% (n = 418) the combination therapy. The torsemide-treated and combination-treated patients had worse heart function and higher furosemide equivalent. Univariable Cox proportional hazards models showed that the combination group had worse outcomes (all-cause HR = 2.044, P = 0.008; CV HR = 1.988, P = 0.011), while torsemide was associated with an outcome (all-cause HR = 1.640, P = 0.078; CV HR = 1.509, P = 0.147) similar to that of furosemide. After IPW, torsemide was associated with a nominally lower mortality compared with furosemide (all-cause HR = 0.738, P = 0.222; CV HR = 0.667, P = 0.110), and the association between the combination treatment and increased mortality was no longer statistically significant (all-cause HR = 1.207, P = 0.470;CV HR = 1.174, P = 0.540).We found that torsemide and the combination strategy had similar outcomes when compared with furosemide. However, considering the lack of diuretic randomized clinical trials (RCTs) conducted with the aim of exploring the effect on mortality of different diuretic treatments, prospective trials are needed to investigate the effect of different diuretic strategies in chronic HF.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2018) conducted a cohort in Chronic heart failure (n=956). Torsemide vs. Furosemide was evaluated on One-year all-cause mortality (HR 0.738, 95% CI 0.452-1.020, p=0.222). Discharge on torsemide was not associated with a significant difference in one-year all-cause mortality compared to furosemide in patients with chronic heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: